GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnology and cell & gene therapy markets
GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnol
- GeminiBio opens new cGMP bioprocess liquid manufacturing facility, expanding capabilities to better serve the biotechnol
GeminiBio's new large-volume liquid manufacturing facility significantly expands the company's cGMP bioprocess liquid manufacturing capacity. - In addition to existing 500-liter and 1,000-liter formulation tanks, the new manufacturing facility includes one 5,000-liter and two 10,000-liter stainless steel formulation tanks.
- GeminiBio's enhanced manufacturing capacity and capability will allow the company to further simplify and streamline customer's manufacturing workflows, while also improving assurance of supply.
- "We are particularly excited to support the cell and gene therapy markets, including plasmid DNA and viral vector manufacturing, given our ability to address the unique requirements that these manufacturing processes require."